Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Population pharmacokinetic analysis and pharmacogenetics of raltegravir in HIV-positive and healthy individuals.
Arab-Alameddine M, Fayet-Mello A, Lubomirov R, Neely M, di Iulio J, Owen A, Boffito M, Cavassini M, Günthard HF, Rentsch K, Buclin T, Aouri M, Telenti A, Decosterd LA, Rotger M, Csajka C; Swiss HIV Cohort Study Group. Arab-Alameddine M, et al. Among authors: lubomirov r. Antimicrob Agents Chemother. 2012 Jun;56(6):2959-66. doi: 10.1128/AAC.05424-11. Epub 2012 Feb 27. Antimicrob Agents Chemother. 2012. PMID: 22371894 Free PMC article.
ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir.
Lubomirov R, di Iulio J, Fayet A, Colombo S, Martinez R, Marzolini C, Furrer H, Vernazza P, Calmy A, Cavassini M, Ledergerber B, Rentsch K, Descombes P, Buclin T, Decosterd LA, Csajka C, Telenti A; Swiss HIV Cohort Study. Lubomirov R, et al. Pharmacogenet Genomics. 2010 Apr;20(4):217-30. doi: 10.1097/FPC.0b013e328336eee4. Pharmacogenet Genomics. 2010. PMID: 20139798
Association of pharmacogenetic markers with premature discontinuation of first-line anti-HIV therapy: an observational cohort study.
Lubomirov R, Colombo S, di Iulio J, Ledergerber B, Martinez R, Cavassini M, Hirschel B, Bernasconi E, Elzi L, Vernazza P, Furrer H, Günthard HF, Telenti A; Swiss HIV Cohort Study. Lubomirov R, et al. J Infect Dis. 2011 Jan 15;203(2):246-57. doi: 10.1093/infdis/jiq043. Epub 2010 Dec 9. J Infect Dis. 2011. PMID: 21288825 Free PMC article.
Pharmacogenetics-based population pharmacokinetic analysis of etravirine in HIV-1 infected individuals.
Lubomirov R, Arab-Alameddine M, Rotger M, Fayet-Mello A, Martinez R, Guidi M, di Iulio J, Cavassini M, Günthard HF, Furrer H, Marzolini C, Bernasconi E, Calmy A, Buclin T, Decosterd LA, Csajka C, Telenti A; Swiss HIV Cohort Study. Lubomirov R, et al. Pharmacogenet Genomics. 2013 Jan;23(1):9-18. doi: 10.1097/FPC.0b013e32835ade82. Pharmacogenet Genomics. 2013. PMID: 23111422
Population pharmacokinetic modelling and evaluation of different dosage regimens for darunavir and ritonavir in HIV-infected individuals.
Arab-Alameddine M, Lubomirov R, Fayet-Mello A, Aouri M, Rotger M, Buclin T, Widmer N, Gatri M, Ledergerber B, Rentsch K, Cavassini M, Panchaud A, Guidi M, Telenti A, Décosterd LA, Csajka C; Swiss HIV Cohort Study. Arab-Alameddine M, et al. Among authors: lubomirov r. J Antimicrob Chemother. 2014 Sep;69(9):2489-98. doi: 10.1093/jac/dku131. Epub 2014 May 12. J Antimicrob Chemother. 2014. PMID: 24821595 Free article.
[General concepts and study methods in pharmacogenetics].
Lubomirov R, Telenti A, Rotger M. Lubomirov R, et al. Enferm Infecc Microbiol Clin. 2008 May;26 Suppl 6:4-9. doi: 10.1016/s0213-005x(08)76506-6. Enferm Infecc Microbiol Clin. 2008. PMID: 18680690 Spanish.
In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function.
di Iulio J, Fayet A, Arab-Alameddine M, Rotger M, Lubomirov R, Cavassini M, Furrer H, Günthard HF, Colombo S, Csajka C, Eap CB, Decosterd LA, Telenti A; Swiss HIV Cohort Study. di Iulio J, et al. Among authors: lubomirov r. Pharmacogenet Genomics. 2009 Apr;19(4):300-9. doi: 10.1097/FPC.0b013e328328d577. Pharmacogenet Genomics. 2009. PMID: 19238117
Contribution of genetic background, traditional risk factors, and HIV-related factors to coronary artery disease events in HIV-positive persons.
Rotger M, Glass TR, Junier T, Lundgren J, Neaton JD, Poloni ES, van 't Wout AB, Lubomirov R, Colombo S, Martinez R, Rauch A, Günthard HF, Neuhaus J, Wentworth D, van Manen D, Gras LA, Schuitemaker H, Albini L, Torti C, Jacobson LP, Li X, Kingsley LA, Carli F, Guaraldi G, Ford ES, Sereti I, Hadigan C, Martinez E, Arnedo M, Egaña-Gorroño L, Gatell JM, Law M, Bendall C, Petoumenos K, Rockstroh J, Wasmuth JC, Kabamba K, Delforge M, De Wit S, Berger F, Mauss S, de Paz Sierra M, Losso M, Belloso WH, Leyes M, Campins A, Mondi A, De Luca A, Bernardino I, Barriuso-Iglesias M, Torrecilla-Rodriguez A, Gonzalez-Garcia J, Arribas JR, Fanti I, Gel S, Puig J, Negredo E, Gutierrez M, Domingo P, Fischer J, Fätkenheuer G, Alonso-Villaverde C, Macken A, Woo J, McGinty T, Mallon P, Mangili A, Skinner S, Wanke CA, Reiss P, Weber R, Bucher HC, Fellay J, Telenti A, Tarr PE; MAGNIFICENT Consortium; INSIGHT; Swiss HIV Cohort Study. Rotger M, et al. Among authors: lubomirov r. Clin Infect Dis. 2013 Jul;57(1):112-21. doi: 10.1093/cid/cit196. Epub 2013 Mar 26. Clin Infect Dis. 2013. PMID: 23532479 Free PMC article.
36 results